atrial-natriuretic-factor and bardoxolone-methyl
atrial-natriuretic-factor has been researched along with bardoxolone-methyl* in 1 studies
Other Studies
1 other study(ies) available for atrial-natriuretic-factor and bardoxolone-methyl
Article | Year |
---|---|
The NRF2 activator DH404 attenuates adverse ventricular remodeling post-myocardial infarction by modifying redox signalling.
The novel synthetic triterpenoid, bardoxolone methyl, has the ability to upregulate cytoprotective proteins via induction of the nuclear factor erythroid-2-related factor 2 (Nrf2) pathway. This makes it a promising therapeutic agent in disease states characterized by dysregulated oxidative signalling. We have examined the effect of a Nrf2 activator, dihydro-CDDO-trifluoroethyl amide (DH404), a derivative of bardoxolone methyl, on post-infarct cardiac remodeling in rats.. DH404, administered from day 2 post myocardial infarction (MI: 30min transient ischemia followed by reperfusion) resulted in almost complete protection against adverse ventricular remodeling as assessed at day 28 (left ventricular end-systolic area: sham 0.14±0.01cm. The bardoxolone derivative DH404 significantly attenuated cardiac remodeling post MI, at least in part, by re-coupling of eNOS and increasing the functional interaction of Grx1 with eNOS. This agent may have clinical benefits protecting against post MI cardiomyopathy. Topics: Angiotensin II; Animals; Atrial Natriuretic Factor; Cells, Cultured; Disease Models, Animal; Fibronectins; Glutaredoxins; Heart; Humans; Male; Myocardial Infarction; NF-E2-Related Factor 2; Nitric Oxide Synthase Type III; Oleanolic Acid; Oxidation-Reduction; Rats; Rats, Sprague-Dawley; RNA, Small Interfering; Signal Transduction; Ventricular Remodeling | 2017 |